In starved antibiotic field, Melinta soars as FDA grants speedy drug review
Such is the state of affairs in antibiotic land that the FDA agreeing to priority review an application to expand the use of an antibiotic can rocket up a stock more than two-fold.
On Wednesday, Melinta Therapeutics said its approved antibiotic Baxdela had been granted priority review for use in community-acquired bacterial pneumonia (CAPB). The FDA is expected to make its decision by October 24. Shares of the Connecticut drugmaker $MLNT catapulted, closing up nearly 224% at $6.41.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.